Literature DB >> 28973196

Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs.

Pamela S Belperio1, Maggie Chartier1, David B Ross1, Poonam Alaigh1, David Shulkin1.   

Abstract

The U.S. Department of Veterans Affairs (VA) is the nation's largest care provider for hepatitis C virus (HCV)-infected patients and is uniquely suited to inform national efforts to eliminate HCV. An extensive array of delivery of services, policy guidance, outreach efforts, and funding has broadened the reach and capacity of the VA to deliver direct-acting antiviral (DAA) HCV therapy, supported by an infrastructure to effectively implement change and informed by extensive population health data analysis. The VA has treated more than 92 000 HCV-infected veterans since all-oral DAAs became available in January 2014, with cure rates exceeding 90%; only 51 000 veterans in VA care are known to remain potentially eligible for treatment. Key actions advancing the VA's aggressive treatment of HCV infection that are germane to non-VA settings include expansion of treatment capacity through the use of nonphysician providers, video telehealth, and electronic technologies; expansion of integrated care to address psychiatric and substance use comorbidities; and electronic data tools for patient tracking and outreach. A critical component of effective implementation has been building infrastructure through the creation of regional multidisciplinary HCV Innovation Teams, whose system redesign efforts have produced innovative HCV practice models addressing gaps in care while providing more efficient and effective HCV management for the populations they serve. Financing for HCV treatment and infrastructure resources coupled with reduced drug prices has been paramount to the VA's success in curing HCV infection. The VA is poised to share and extend best practices to other health care organizations and providers delivering HCV care, contributing to a concerted effort to reduce the overall burden of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28973196     DOI: 10.7326/M17-1073

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  34 in total

1.  Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus: The Veteran Birth Cohort.

Authors:  Basile Njei; Denise Esserman; Supriya Krishnan; Michael Ohl; Janet P Tate; Ronald G Hauser; Tamar Taddei; Joseph Lim; Amy C Justice
Journal:  Med Care       Date:  2019-04       Impact factor: 2.983

2.  S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder.

Authors:  Jennifer M Loftis; Juno Valerio; Jonathan Taylor; Elaine Huang; Rebekah Hudson; Patricia Taylor-Young; Michael Chang; Samuel B Ho; Eric Dieperink; Juan Luis Miranda; Peter Hauser
Journal:  Alcohol Clin Exp Res       Date:  2018-06-28       Impact factor: 3.455

3.  Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals.

Authors:  Lauren A Beste; Pamela Green; Kristin Berry; Pamela Belperio; George N Ioannou
Journal:  JAMA       Date:  2020-09-08       Impact factor: 56.272

Review 4.  Population-based screening of hepatitis C virus in the United States.

Authors:  John Bian; Andrew D Schreiner
Journal:  Curr Opin Gastroenterol       Date:  2019-05       Impact factor: 3.287

5.  Role of the US Veterans Health Administration Clinical Pharmacy Specialist Provider: Shaping the Future of Comprehensive Medication Management.

Authors:  M Shawn McFarland; Julie Groppi; Terri Jorgenson; Tera Moore; Heather Ourth; Andrea Searle; Anthony Morreale
Journal:  Can J Hosp Pharm       Date:  2020-04-01

Review 6.  The Current and Future Use of Telemedicine in Infectious Diseases Practice.

Authors:  Caitlin E Coombes; Megan E Gregory
Journal:  Curr Infect Dis Rep       Date:  2019-10-19       Impact factor: 3.725

7.  Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment.

Authors:  Elizabeth Le; Grace Chee; Miki Kwan; Ramsey Cheung
Journal:  Dig Dis Sci       Date:  2021-03-26       Impact factor: 3.199

8.  Strategy Configurations Directly Linked to Higher Hepatitis C Virus Treatment Starts: An Applied Use of Configurational Comparative Methods.

Authors:  Vera Yakovchenko; Edward J Miech; Matthew J Chinman; Maggie Chartier; Rachel Gonzalez; JoAnn E Kirchner; Timothy R Morgan; Angela Park; Byron J Powell; Enola K Proctor; David Ross; Thomas J Waltz; Shari S Rogal
Journal:  Med Care       Date:  2020-05       Impact factor: 2.983

9.  Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care.

Authors:  Brian J Mcmahon; Lisa Townshend-Bulson; Chriss Homan; Prabhu Gounder; Youssef Barbour; Annette Hewitt; Dana Bruden; Hannah Espera; Julia Plotnik; James Gove; Timothy J Stevenson; Sarah V Luna; Brenna C Simons
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

10.  Use of Telehealth Expedites Evaluation and Listing of Patients Referred for Liver Transplantation.

Authors:  Binu V John; Eleanor Love; Bassam Dahman; Nargiza Kurbanova; Venkata Rajesh Konjeti; Latha Thankam Sundaram; Yangyang Deng; Sean Aubuchon; Douglas Heuman; Jasmohan S Bajaj; Hochong Gilles; Michael Chang; Rehan Qayyum; Mohammad S Siddiqui
Journal:  Clin Gastroenterol Hepatol       Date:  2019-12-27       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.